Table 3. Study characteristics of the clinical trials of magnesium on ischemic stroke.

g: grams, Mg: magnesium, IV: intravenous, ml: milliliters,

Study, year of publication	Drug	Country	Study design	Number of patients in Treatment group	Number of patients Control	Dose, route and duration, onset of symptoms
Aslanyan et al. (2007) [5]	Magnesium- Sulfate	United Kingdom	Post-hoc analysis of a randomized, multicenter trial   Hemorrhagic stroke was excluded. There was the inclusion of only two of the classic lacunar syndromes (pure motor and sensorimotor strokes)	383	382	IV, continued for 24 hours within 12 hours of the onset of stroke, continued for 24 hours
Pan et al. (2017) [6]	Potassium-magensium salt	Taiwan	Double blind, multicenter, randomized control trial   The patients were divided into three groups: Regular salt, potassium enriched salt and magnesium potassium enriched salt.	Potassium - magnesium-enriched salt (n = 95)	(n = 99) (regular salt) (Na/Cl salt) (n= 97) (potassium enriched salt) (K salt)	4.1 mmol for magnesium and 44.8 mmol for potassium, oral, for six months
Shkirkova et al. (2017) 12]	Magnesium-Sulfate	United States	Randomized, blinded and placebo-controlled trial   Patients were divided into five quintiles based on the blood Mg levels.	569	561	15-minute loading dose, infusion then, 4g magnesium-sulfate or placebo followed by a 24-hour maintenance dose of 16 g magnesium-sulfate or matched placebo over 24 hours, IV, within 24 hours of the onset of symptoms
Saver et al. (2015) [13]	Magnesium-Sulfate	United States	Phase 3, multicenter, randomized, double-blind, placebo-controlled, pivotal clinical trial.	855	840	Bolus (loading) dose contained 4 g of magnesium sulfate in 54 ml of normal saline infused over a period of 15 minutes; the maintenance infusion contained 16 g of magnesium sulfate diluted in 240 ml of 0.9% normal saline, infused at a rate of 10 ml per hour for 24 hours, IV, within two hours of symptoms